- Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1
Sanjeev Kumar et al, 2019, Journal of Medicinal Chemistry CrossRef - IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
Adaobi Amobi-McCloud et al, 2021, Frontiers in Immunology CrossRef - Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer
Lukas Lanser et al, 2020, Frontiers in Immunology CrossRef - Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
Yvonne Grobben et al, 2021, Frontiers in Immunology CrossRef - Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer
Takemasa Tsuji et al, 2020, Oncotarget CrossRef - Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients
Kashif Asghar et al, 2020, World Journal of Clinical Oncology CrossRef - IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis
Houmei Wang et al, 2022, International Journal of Molecular Sciences CrossRef - What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
Theodoros Eleftheriadis, 2018, Frontiers in Immunology CrossRef